Huons

Olopatadine hydrochloride eye drop for allergic conjunctivitis, Korea's first multi-dose preservative-free olopatadine product, dosed once daily; launched in May 2026.

Glaucoma candidate combining a carbonic anhydrase inhibitor (CAI) and a beta-blocker; in Phase 3.

FPR2 agonist candidate for dry eye disease; in Phase 2.

Oral, gut-acting selective TG2 inhibitor aimed at fibrostenosing Crohn's disease; a preclinical-stage candidate.

Vaccine division set up in March 2026 that has brought in five vaccine products using the company's cold-chain infrastructure and injectable sales network; in October 2026 it added an exclusive Korean distribution agreement for the live Japanese encephalitis vaccine IMOJEV.

Launched Hurotadine 0.7%, Korea's first multi-dose preservative-free olopatadine eye drop.

Was selected for three government-funded new-drug co-development projects with partners working on an mRNA-LNP eye drop, the ADC candidate PBX-004 (Pinobio) and the peptide anticancer candidate Pearl-101.

Signed an exclusive Korean distribution agreement with Substipharm Biologics, part of France's Substipharm group, for the live Japanese encephalitis vaccine IMOJEV.

Presented preclinical results for HUC1A-626, a fibrostenosing Crohn's disease candidate, in a poster at UEG Week 2026 in Barcelona, Spain.